Effect of growth hormone replacement on BMD in adult-onset growth hormone deficiency.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Who Took Part

According to the abstract, 67 men were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

BMD was assessed before treatment and at 6, 12, 18, and 24 mo of treatment.

Fifty-four subjects completed the protocol.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Biomarkers, Bone Density, Growth Hormone, Hormone Replacement Therapy, Hypopituitarism, Lumbar Vertebrae and Sex Factors.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 67 men.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2007 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.